The facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates
Granules India said its Gagillapur facility in Hyderabad has completed US FDA inspection without any observations. “The company’s Gagillapur facility located in Hyderabad, Telangana has successfully completed US FDA inspection without any observations,” Granules India said in a BSE filing.
The facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs).
PTI
Comments are closed.